Sartorius vz. Aktie
WKN: 716563 / ISIN: DE0007165631
|
17.02.2025 10:00:11
|
EQS-News: Sartorius releases Annual Report for 2024
|
EQS-News: SARTORIUS AG
/ Key word(s): Annual Report
Göttingen, Germany | February 17, 2025
Sartorius releases Annual Report for 2024 The life science group Sartorius today released its Annual Report for 2024. The document is available at the following link: https://ir-reports.sartorius.com/en/ag/fy-2024/ Financial calendar March 27, 2025 Annual Shareholders’ Meeting April 16, 2025 Publication of the first quarter results January to March 2025 July 22, 2025 Publication of the half-year results January to June 2025 October 16, 2025 Publication of the nine-month results January to September 2025 A profile of Sartorius Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. Visit our Newsroom and follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com
17.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2086757 |
| End of News | EQS News Service |
|
|
2086757 17.02.2025 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius AG Vz.mehr Nachrichten
|
05.11.25 |
Börse Frankfurt in Rot: MDAX fällt letztendlich (finanzen.at) | |
|
05.11.25 |
Börse Frankfurt in Rot: MDAX verbucht zum Start Verluste (finanzen.at) | |
|
04.11.25 |
TecDAX aktuell: Das macht der TecDAX nachmittags (finanzen.at) | |
|
04.11.25 |
Minuszeichen in Frankfurt: So performt der TecDAX mittags (finanzen.at) | |
|
04.11.25 |
TecDAX-Wert Sartorius vz-Aktie: So viel Gewinn hätte ein Investment in Sartorius vz von vor 10 Jahren eingebracht (finanzen.at) | |
|
04.11.25 |
Schwacher Handel: TecDAX verliert zum Start des Dienstagshandels (finanzen.at) | |
|
04.11.25 |
Zurückhaltung in Frankfurt: MDAX fällt zum Start des Dienstagshandels zurück (finanzen.at) | |
|
03.11.25 |
Gute Stimmung in Frankfurt: TecDAX zeigt sich letztendlich fester (finanzen.at) |
Analysen zu Sartorius AG Vz.mehr Analysen
| 22.10.25 | Sartorius vz. Outperform | RBC Capital Markets | |
| 21.10.25 | Sartorius vz. Buy | Jefferies & Company Inc. | |
| 20.10.25 | Sartorius vz. Neutral | Goldman Sachs Group Inc. | |
| 17.10.25 | Sartorius vz. Buy | Deutsche Bank AG | |
| 17.10.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. |
Aktien in diesem Artikel
| Sartorius AG Vz. | 222,80 | 0,13% |
|